A ntineutrophil cytoplasmic antibody (ANCA)À associated vasculitis (AAV) is characterized histologically by small vessel inflammation with few or no immune deposits. 1, 2 Renal involvement is initially marked by crescentic glomerulonephritis with fibrinoid necrosis, and over time by glomerular sclerosis, fibrous crescents, and tubulointerstitial fibrosis. 2, 3 Various histologic markers carry prognostic significance for renal survival. The percentage of normal glomeruli and active cellular crescents are associated with renal function recovery, but the percentage of global sclerosis, fibrous crescents, and tubulointerstitial disease predict poor outcomes. 2, [4] [5] [6] [7] [8] Rarely, the initial biopsy falls outside traditional histologic findings and is devoid of active glomerulonephritis, posing a prognostic and therapeutic dilemma for clinicians. It is believed that such patients experience prolonged subclinical disease, and by the time they present, they have severe renal dysfunction and no symptomatic or histologic evidence of active inflammation. In the setting of apparent irreversible damage and no acute activity, the benefit of an immunosuppression regimen that carries nonnegligible toxicity is unclear. There is currently no data on outcomes or optimal therapy for these patients, and the impact of immunosuppression on renal and overall survival in this population is unknown.
We illustrate a series of patients with renal-limited AAV who presented without systemic evidence of inflammation and who had initial kidney biopsies that were devoid of active glomerulonephritis. The purpose of this study was to describe clinical, histologic, and therapeutic parameters in a group of patients with this rare clinical presentation. As an attempt to gain insight into the role of immunosuppression for these patients, our primary aim was to explore the relationship between receipt of immunosuppression and the development of end-stage renal disease (ESRD) and vasculitis relapse.
METHODS

Study Population
The study population was derived from a retrospective cohort from 8 
Clinical Data Acquisition
Age, sex, disease phenotype, ANCA serotype, new diagnosis versus established diagnosis, and clinical features at presentation were ascertained. Estimated glomerular filtration rate (eGFR) at presentation, 6 months, and at last follow-up, occurrence of disease relapse, need for renal replacement therapy at the time of presentation and at last follow-up, details of induction therapy, and maintenance immunosuppression were extracted from review of clinical source documents. All kidney biopsies were reviewed to ensure there was no evidence of active renal vasculitis. Adverse events, including new-onset diabetes, episodes of leukopenia (white blood count <4000/ mm 3 ), and infections that required hospitalization were recorded.
Laboratory Data Acquisition
Serum creatinine at the time of diagnosis was recorded according to the local laboratory. ANCA testing was done by standard indirect immunofluorescence assay on ethanol fixed neutrophils for cytoplasmic ANCA and perinuclear ANCA. Proteinase-3 and myeloperoxidase (MPO) testing by direct enzyme-linked immunosorbent assay were performed according to the local laboratory.
Outcomes
We evaluated outcomes of ESRD and vasculitis relapse during follow-up.
Study Definitions
Disease phenotype was defined according to the Chapel Hill Consensus nomenclature. 1 Renal function was measured using the 4-variable Modification of Diet in Renal Disease formula for eGFR. 9 ESRD was defined by the ongoing need for renal replacement therapy for >3 months. Hematuria was defined as urinary red blood cell count of >5 per high-power field. Kidney involvement was defined by diagnostic renal biopsy. Lack of disease activity was defined by absence of cellular crescents, fibrocellular crescents, and necrotizing lesions on renal biopsy. Interstitial fibrosis was graded as mild, moderate, and severe depending on extent of involvement (<25%, 25%À50%, >50%). Remission was defined as stabilization or improvement in serum creatinine, resolution of hematuria, and absence of extrarenal signs of vasculitis for at least 1 month. Relapse was defined as occurrence of signs and symptoms of vasculitis in any organ that required a change in immunosuppressive therapy after achieving remission.
Statistical Analyses
All descriptive data were presented as median with range or mean AE SD. We described the differences between clinical and histologic parameters between the ESRD groups. Data were tabulated for the full sample and were also divided by ESRD and relapse group. The group differences were tested using Student's t-test and Fisher exact tests. All tests of significance were 2-sided, and differences were considered significant if the P value was <0.05. presented with subacute weight loss, but otherwise, these individuals lacked systemic symptoms, and clinical presentations were limited to acute kidney injury (AKI) with active urinary sediment. Median age at time of initial biopsy was 62 years (range: 40À76 years). Eighty-eight percent of patients were positive for MPO-ANCA. Mean AE SD eGFR was 24 AE 20 ml/min per 1.73 m 2 , and 5 patients (31%) required dialysis at presentation.
RESULTS
Patient Characteristics
Mean AE SD sampled glomeruli was 28 AE 16. All biopsy specimens were devoid of fibrinoid necrosis, cellular crescents, and fibrocellular crescents. Mean AE SD normal glomeruli was 16 AE 25%, percentage of global sclerosis was 47 AE 32%, and 27 AE 26% of glomeruli exhibited fibrous crescents. All biopsies had moderate to severe interstitial fibrosis and tubular atrophy, with 9 revealing severe interstitial fibrosis and tubular atrophy.
Induction immunosuppression was given to 12 patients (75%); 6 received initial pulse methylprednisolone, and 9 and 3 received cyclophosphamide and rituximab, respectively. Of the 12 patients, 4 were dialysis-dependent at entry, and the remaining 8 patients had a baseline mean AE SD eGFR of 30 AE 19 ml/ min per 1.73 m 2 . No patient received plasmapheresis. Information on duration of steroid use was available for 9 patients; median duration was 12 months (range: 1À108 months). Information on duration of cyclophosphamide use was available for 8 patients; the median duration was 1.5 months (range: 1À50 months). There were no reported cases of new-onset diabetes or leukopenia, although information for these variables was only available for 14 patients. Six patients (38%) experienced infections that required hospitalization; all of these patients received immunosuppression. Four (25%) patients died; 2 from infection, 1 from an unknown cause, and another from unrelated head trauma.
Outcomes
Throughout a median follow-up period of 22 months (range: 1À127 months), 6 patients (38%) developed ESRD. Clinical, histologic, and therapeutic characteristics of the ESRD and non-ESRD groups are shown in Table 2 . There were no significant differences in age, race, or ANCA type. Patients who developed ESRD had a lower baseline eGFR (8 AE 5 ml/min per 1.73 m 2 vs. 35 AE 18 ml/min per 1.73 m 2 ; P ¼ 0.001). Patients who developed ESRD were also more likely to be on dialysis at presentation (83% vs. 0%; P ¼ 0.001). None of the patients who initially required dialysis recovered renal function. The percentage of global sclerosis was higher in the ESRD group than in the non-ESRD group (62 AE 31% vs. 38 AE 31%; P ¼ 0.17), and the non-ESRD group had more normal glomeruli than the ESRD group (21 AE 30%; P ¼ 0.25), but these findings were not statistically significant. The 2 groups did not differ with respect to the percentage of fibrous crescents or degree of interstitial fibrosis and tubular atrophy, receipt of immunosuppression, infection rate, or mortality. Of the 4 patients who were dialysis-dependent at entry and received induction therapy, none recovered renal function. Of the 8 patients who did not require dialysis at entry and received immunosuppression, the mean AE SD eGFR at 1 year was 34 AE 23 ml/min per 1.73 m 2 in 6 patients. One patient did not have a follow-up serum creatinine at 1 year, and the other patient died due to infection.
Four patients experienced disease relapse (at 2, 12, 13, and 69 months after initial biopsy). Relapses consisted of cutaneous manifestations, pulmonary hemorrhage, and recurrent AKI, with active cellular crescents on repeat kidney biopsy. Table 2 displays characteristics of the 2 relapse groups. Those who relapsed were less likely to have received immunosuppression than those who did not relapse (25% vs. 92%; relative risk: 0.26; risk difference: 67%; P ¼ 0.03). Only 1 of 12 patients who received immunosuppression relapsed; this patient received cyclophosphamide for 1 month before stopping therapy and then developed pulmonary hemorrhage 1 month later. The 2 groups did not differ with respect to age, race, ANCA type, presenting eGFR, initial dialysis requirement, specific induction regimen, infection risk, or mortality.
DISCUSSION
Overall, we found no significant relationship between receipt of induction immunosuppression and renal recovery. However, those who received immunosuppression were less likely to relapse. Like the general population with renal-limited AAV, those with a lower eGFR had an increased risk for ESRD. Histologic characteristics thought to carry prognostic significance were not of great value in these patients.
2,4-7,10
The decision to use immunosuppressive therapy in patients without histologic or systemic evidence of disease activity is complex. One of our primary aims was to begin to describe the possible risks and benefits of immunosuppression in the absence of identifiable inflammation. In patients with active biopsy lesions, there was similar debate in the past about the threshold of renal damage, at which point the chance of renal recovery with immunosuppression might be deemed futile. Several groups independently found that a substantial proportion of patients who initially required dialysis recovered, and concluded that a trial of immunosuppression with glucocorticoids and cyclophosphamide should be considered regardless of renal function at diagnosis. [11] [12] [13] Lee et al. evaluated patients who presented with eGFR <15 ml/min per 1.73 m 2 , and found that even among those with maximal chronicity index scores, the probability of treatment response was >14%. 11 Hogan et al. reported that more than one-half of those who presented with eGFR <10 ml/min reached remission with immunosuppression treatment. 12 However, the patients in these studies all had clear evidence of active inflammation at presentation.
Unlike existing literature, our findings suggested that immunosuppression might not alter renal outcomes in the absence of identifiable inflammation. 11, 12, 14 However, those who receive immunosuppression at presentation might be less likely to experience relapse (with renal and extrarenal organ involvement) than patients who do not receive immunosuppression. We recommend this consideration be factored into decision making and included in treatment discussions with patients. We cannot comment on the choice and duration of therapy because this was determined by the local physician and therefore highly variable. We were not able to analyze the impact of steroid or cyclophosphamide duration on outcomes due to missing information on these variables. 15 We also could not comment on the role of plasmapheresis in these patients, because most presented at a time when plasmapheresis was primarily restricted to those with severe pulmonary hemorrhage and was not routinely used for severe renal dysfunction. 16 The benefit of relapse prevention should be weighed against the risk of infection in the individual. In this sample, infections occurred in both immunosuppression groups (8% risk difference between the immunosuppressed group and nonimmunosuppressed group; P ¼ 0.57). Infections in the immunosuppressed group occurred after 1, 6, 12, and 20 months of therapy. All immunosuppressed patients received appropriate infection prophylaxis, and there were no cases of preventable infection (such as with Pneumocystis jiroveci pneumonia).
Our findings agreed with past studies on the relationship between initial renal function and renal survival. In 2003, Vergunst et al. found that initial eGFR was the strongest predictor of renal function at 1 year. 8 In 2010, Berden et al. found that baseline eGFR was an 
